Drivers of the Global Uveitis Treatment Market
Over the forecast period, the high prevalence of uveitis is expected to drive growth in the worldwide Uveitis Treatment Market. According to the study 'Epidemiology of uveitis in urban Australia,' published in the journal Clinical and Experimental Ophthalmology in April 2019, the incidence of uveitis was 21.54 per 100 000 person?years. The prevalence of the disease was 36.27 per 100 000 people at the time.
Furthermore, the rising prevalence of autoimmune illnesses is likely to boost market growth. According to a research published in February 2019 in the journal Neurology by the National MS Society, almost 1 million persons in the United States had multiple sclerosis in 2017.
Opportunities in the Global Uveitis Treatment Market
Over the projected period, promising compounds in clinical trials are expected to provide lucrative growth prospects for participants in the worldwide uveitis therapy market. Tarsius Pharma, a clinical-stage biopharmaceutical startup, for example, concluded patient recruitment in its TRS01 Phase I/II trial in patients with active anterior non-infectious uveitis in June 2020.
The high prevalence of rheumatoid arthritis is also projected to boost market expansion. According to the article "Global, regional, and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017," published in the Journal of the American College of Rheumatology, "global, regional, and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017,"
Read More: https://www.coherentmarketinsights.com/market-insight/uveitis-treatment-market-1094
